Here’s Why You Should Retain Myriad Genetics (MYGN) for Now Posted byZacks Equity Research October 4, 2021 Leave a comment on Here’s Why You Should Retain Myriad Genetics (MYGN) for Now Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.